Cargando…

FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis

Patients with chronic kidney disease (CKD) are prone to developing cardiac hypertrophy and fibrosis, which is associated with increased fibroblast growth factor 23 (FGF23) serum levels. Elevated circulating FGF23 was shown to induce left ventricular hypertrophy (LVH) via the calcineurin/NFAT pathway...

Descripción completa

Detalles Bibliográficos
Autores principales:	Böckmann, Ineke, Lischka, Jonas, Richter, Beatrice, Deppe, Jennifer, Rahn, Anja, Fischer, Dagmar-Christiane, Heineke, Jörg, Haffner, Dieter, Leifheit-Nestler, Maren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770314/ https://www.ncbi.nlm.nih.gov/pubmed/31540546 http://dx.doi.org/10.3390/ijms20184634

Ejemplares similares

Paracrine Effects of FGF23 on the Heart
por: Leifheit-Nestler, Maren, et al.
Publicado: (2018)

How FGF23 shapes multiple organs in chronic kidney disease
por: Leifheit-Nestler, Maren, et al.
Publicado: (2021)

FGF23 and Phosphate–Cardiovascular Toxins in CKD
por: Vogt, Isabel, et al.
Publicado: (2019)

Cardiac FGF23 expression correlates with left ventricular hypertrophy in patients with chronic kidney disease
por: Leifheit-Nestler, Maren, et al.
Publicado: (2014)

Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy
por: Eitner, Fiona, et al.
Publicado: (2022)

Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice
por: Leifheit-Nestler, Maren, et al.
Publicado: (2021)

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease—A Pediatric Perspective
por: Grund, Andrea, et al.
Publicado: (2021)

Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23
por: Leifheit-Nestler, Maren, et al.
Publicado: (2018)

Renal effects of growth hormone in health and in kidney disease
por: Haffner, Dieter, et al.
Publicado: (2021)

Muscle and Bone Impairment in Infantile Nephropathic Cystinosis: New Concepts
por: Haffner, Dieter, et al.
Publicado: (2022)

Rickets guidance: part II—management
por: Haffner, Dieter, et al.
Publicado: (2022)

Rickets guidance: part I—diagnostic workup
por: Haffner, Dieter, et al.
Publicado: (2021)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

FGF23 Actions on Target Tissues—With and Without Klotho
por: Richter, Beatrice, et al.
Publicado: (2018)

Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity
por: Leifheit-Nestler, Maren, et al.
Publicado: (2013)

FGF23 and its role in X-linked hypophosphatemia-related morbidity
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2019)

The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022)

A NFAT decoy approach to inhibit cardiac hypertrophy
por: Heineke, Joerg
Publicado: (2021)

Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload
por: Slavic, Svetlana, et al.
Publicado: (2017)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

Phosphate and FGF-23
por: Jüppner, Harald
Publicado: (2011)

FGF23 and inflammation
por: Sharaf El Din, Usama A A, et al.
Publicado: (2017)

Editorial: Mineral and Bone Disorder in CKD
por: Printza, Nikoleta, et al.
Publicado: (2022)

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
por: Okamoto, Kohei, et al.
Publicado: (2021)

High FGF23 Levels Failed to Predict Cardiac Hypertrophy in Animal Models of Hyperphosphatemia and Chronic Renal Failure
por: Moench, Ian, et al.
Publicado: (2021)

Targeting cardiac hypertrophy through a nuclear co‐repressor
por: Grund, Andrea, et al.
Publicado: (2019)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23)
por: Feger, Martina, et al.
Publicado: (2021)

DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease
por: Dussold, Corey, et al.
Publicado: (2019)

Erratum to: Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
Publicado: (2022)

Indoxyl sulfate induces left ventricular hypertrophy via the AhR-FGF23-FGFR4 signaling pathway
por: Kishimoto, Hiroshi, et al.
Publicado: (2023)

FGF-23 in bone biology
por: Wesseling-Perry, Katherine
Publicado: (2009)

FGF23, Biomarker or Target?
por: Rodelo-Haad, Cristian, et al.
Publicado: (2019)

Pleiotropic Actions of FGF23
por: Erben, Reinhold G.
Publicado: (2017)

Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants
por: Enlund-Cerullo, Maria, et al.
Publicado: (2023)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce
por: Bacchetta, Justine, et al.
Publicado: (2023)

Heavy Ion RAA summary Plots 2022
por: The ATLAS collaboration
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9k5e9p9me3il60s9lo61rv5ho1